PEG-MGF
Also known as: PEGylated Mechano Growth Factor
PEG-MGF is the pegylated form of Mechano Growth Factor (MGF), the distinct 24-amino-acid C-terminal E-peptide encoded by the IGF-1Ec splice variant (IGF-1Eb in rodents) that is transiently upregulated in muscle after mechanical loading or damage. MGF is related to but pharmacologically distinct from mature IGF-1 and IGF-1 LR3. Pegylation extends its half-life from minutes to several hours, and the compound is marketed as a research chemical for muscle repair protocols. It is not FDA-approved for any indication.
Pricing for PEG-MGF
Live vendor pricing, normalized to $/mg so sizes compare fairly — fused with each seller's Merit trust score and latest independent COA purity. Prices refresh daily.
COAs for PEG-MGF
8 third-party tests across 5 vendors. Each card links to the full report.
For
PEG-MGF with Trehalose
by Skye Peptides· batch PMG26-05-001
For
PEG-MGF
by BioLongevity Labs· batch QC260699
For
PEG-MGF
by Ion Peptide· batch PMGF-121325
For
PEG-MGF
by Simple Peptide· batch PEGM08252025-J
For
PEG-MGF
by Ion Peptide· batch PMGF-010226
Purity not on file
For
PEG-MGF with Trehalose
by Skye Peptides· batch PMG26-05-001
Purity not on file
For
PEG-MGF with Trehalose
by Skye Peptides· batch PMG26-05-001
Purity not on file
For
PEG-MGF
by Peptidegurus· batch cmojgr60i002i9grxmefx6ikp
12 citations indexed for PEG-MGF
rct · 2025
Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies
This study is a pre-screening process used to assess participants' potential eligibility for Roche interventional Alzheimer's disease studies.
rct · 2021
A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE)
This study is done to find out whether the medicine, semaglutide, has a positive effect on early Alzheimer's disease. Participants will either get semaglutide or placebo (a "dummy" medicine which does not contain any study medicine) - which treatment participants get is decided by an equal chance.
rct · 2018
THALES - Acute STroke or Transient IscHaemic Attack Treated With TicAgreLor and ASA for PrEvention of Stroke and Death
Study to investigate if the study drug ticagrelor and ASA is more effective than Placebo (inactive tablet) and ASA in preventing new stroke events
Study · 2017
The Generation of Dehydroalanine Residues in Protonated Polypeptides: Ion/Ion Reactions for Introducing Selective Cleavages
We examine a gas-phase approach for converting a subset of amino acid residues in polypeptide cations to dehydroalanine (Dha). Subsequent activation of the modified polypeptide ions gives rise to specific cleavage N-terminal to the Dha residue.
rct · 2016
A Study of PEG-somatropin Injection to Treat Children of Turner Syndrome
This study aims to explore the optimal dose of pegylated recombinant human growth hormone (PEG-rhGH) injection to treat children of Turner syndrome (TS), preliminarily evaluate its safety and efficacy and provide scientific and reliable evidence for the medication dosage in Phase 3 clinical trial.
Study · 2013
Intranasal, siRNA Delivery to the Brain by TAT/MGF Tagged PEGylated Chitosan Nanoparticles
Neurodegeneration is characterized by progressive loss of structure and function of neurons. Several therapeutic methods and drugs are available to alleviate the symptoms of these diseases.